#USA #Cambridge #MetaVia #DA-1241 #DA-1726

MetaVia Inc. Reports Q2 2025 Financial Results

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, released its financial results for the second quarter ending June 30, 2025. The company is confident in its pipeline, which includes groundbreaking treatments for obesity and liver-related conditions.

Clinical Progress Highlights

MetaVia's recent achievements include the successful dosing of the first patient in a multi-dose phase 1 clinical trial of DA-1726, aimed at treating obesity. This trial involves a new dosing protocol, extending its duration to 8 weeks to evaluate the maximum tolerated dose (MTD). Previous data from the shorter 4-week administration demonstrated promising results, including an average weight loss of 4.3% among participants on the 32 mg dose. This was accompanied by significant reductions in waist circumference and improved fasting glucose levels. The company plans to disclose additional data from this extended cohort in Q4 2025.

In addition to DA-1726, MetaVia is advancing DA-1241, an innovative oral medication targeting metabolic dysfunction-associated steatohepatitis (MASH). Recent collaborations, including one with Syntekabio, aim to enhance DA-1241's therapeutic potential by exploring additional indications beyond MASH using AI-driven technology. Presentations at the American Diabetes Association's 85th Scientific Sessions emphasized DA-1241's dual function in reducing liver fat and inflammation, highlighting its role in addressing complex metabolic syndromes.

Financial Overview

Financially, MetaVia ended the second quarter with $17.6 million in cash, which is expected to support operations into 2026. The company reported a significant reduction in research and development expenses, totaling approximately $2.3 million for Q2 2025, down from $8.1 million in the same quarter last year. This reduction is primarily attributable to lower direct costs in both DA-1241 and DA-1726 development.

For the second quarter, MetaVia's total operating expenses were approximately $4.3 million, significantly less than the $10.1 million reported during the same period in 2024. Following this positive trend, the net loss narrowed to $4.0 million, or $0.26 per share, representing an improvement compared to the previous year’s $10.1 million net loss.

Future Outlook

Looking ahead, MetaVia is poised to make significant strides in its clinical trials as they continue to evaluate the efficacy of DA-1726 in obesity and DA-1241 in other metabolic disorders. Key milestones, including further results from the 48 mg MAD cohort trial and the potential FDA meeting for DA-1241, are anticipated this year.

Overall, MetaVia's strategic approach and strong financial position offer a promising outlook for addressing unmet medical needs in the cardiometabolic disease space. The company's innovative therapies could reshape treatment paradigms, potentially leading to better health outcomes for individuals affected by these conditions.

For further information regarding their developments and research, investors and stakeholders can visit MetaVia's official website.